Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (67,197,746)	$ (36,294,880)
Net loss attributable to noncontrolling interests		95,132
NET LOSS ATTRIBUTABLE TO ARROWHEAD	(67,197,746)	(36,199,748)
(Gain) loss on disposal of fixed assets	(19,195)	58,878
Change in value of derivatives	(2,446,403)	5,712,335
Acquired in-process research and development	10,142,786
Stock-based compensation	6,706,009	3,758,264
Depreciation and amortization	1,480,656	1,075,238
Amortization of note premiums	945,114	416,291
Noncash gain in equity investment		(87,197)
Non-controlling interest		(95,132)
Changes in operating assets and liabilities:
Receivables		75,000
Other receivables	(620,395)	(517,986)
Other current assets	(2,902,368)	(138,650)
Accounts payable	2,328,360	990,929
Accrued expenses	(2,155,033)	459,691
Other	31,639	(4,480)
NET CASH USED IN OPERATING ACTIVITIES	(53,687,381)	(24,496,567)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for acquisitions	(10,000,000)
Purchases of property and equipment	(1,135,651)	(1,251,987)
Proceeds from sale of fixed assets	500
Purchase of marketable securities		(46,365,528)
Proceeds from sale of marketable securities	19,411,146	6,590,824
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	8,275,995	(41,026,691)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on capital leases and notes payable	(160,162)	(257,178)
Proceeds from issuance of common stock and preferred stock, net		172,641,720
Proceeds from the exercise of warrants and stock options	313,751	12,374,005
NET CASH PROVIDED BY FINANCING ACTIVITIES	153,589	184,758,547
NET INCREASE (DECREASE) IN CASH	(45,257,797)	119,235,289
CASH AT BEGINNING OF PERIOD	132,510,610	19,114,444
CASH AT END OF PERIOD	87,252,813	138,349,733
Supplementary disclosures:
Interest paid	11,153	$ 21,478
Common stock issued to Novartis for asset acquisition	$ 25,000,000